Scinai Immunotherapeutics Ltd
SCNI
Company Profile
Business description
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
Contact
Hadassah Ein Kerem Campus
Jerusalem BioPark, 2nd Floor
Jerusalem
ISRT: +972 89302529
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
31
Stocks News & Analysis
stocks
Vote in favour of merger for undervalued ASX share
We recommend shareholders vote in favor of its proposed merger.
stocks
Are investors missing the boat on this future ASX leader?
The market is underestimating the clear path to profitability.
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,557.40 | 11.70 | -0.14% |
| CAC 40 | 7,721.38 | 86.64 | 1.13% |
| DAX 40 | 20,893.39 | 238.00 | 1.15% |
| Dow JONES (US) | 43,153.13 | 68.42 | -0.16% |
| FTSE 100 | 8,517.80 | 125.90 | 1.50% |
| HKSE | 19,584.06 | 61.17 | 0.31% |
| NASDAQ | 19,338.29 | 172.95 | -0.89% |
| Nikkei 225 | 38,451.46 | 121.14 | -0.31% |
| NZX 50 Index | 13,130.43 | 129.76 | 1.00% |
| S&P 500 | 5,937.34 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,310.40 | 16.60 | -0.20% |
| SSE Composite Index | 3,241.82 | 5.79 | 0.18% |